Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recurrent urinary tract infections.

Anna Virginia M Franco1

  • 1Department of Urogynaecology and Pelvic Reconstruction, 4th Floor Lanesborough Wing, St George's Hospital, Blackshaw Road, London SW17 0QT, UK. avmfranco@yahoo.com

Best Practice & Research. Clinical Obstetrics & Gynaecology
|November 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcomes of modified high uterosacral ligament vault suspension (HUSLS) at vaginal hysterectomy.

International urogynecology journal·2010
Same author

Is there an alternative to pad tests? Correlation of subjective variables of severity of urinary loss to the 1-h pad test in women with stress urinary incontinence.

BJU international·2008
Same author

Tension-free vaginal tape exposure presenting as a recurrent sterile paraurethral abscess.

International urogynecology journal and pelvic floor dysfunction·2005
Same journal

A risk-based classification of late-onset fetal growth disorders according to intrapartum fetal compromise.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

The Cardiac-Fetal-Placental Unit: links between umbilical venous flow and maternal hemodynamics in fetal growth restriction.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Psychosocial interventions for women who are pregnant following a previous reproductive loss: A scoping review.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Controversies in fetal therapy.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Alloimmunisation in pregnancy: current management and future perspectives.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Consensus in prenatal management of Hemolytic disease of the fetus and newborn.

Best practice & research. Clinical obstetrics & gynaecology·2026
See all related articles

Urinary tract infections (UTIs) frequently recur in women, with risk factors including sexual activity and contraception. Research explores treatments like prophylaxis, estrogen, cranberry, and vaccines to prevent recurrent UTIs.

Area of Science:

  • Urology
  • Infectious Diseases
  • Women's Health

Background:

  • Urinary tract infection (UTI) is a common bacterial infection in women, with a significant recurrence rate.
  • Recurrence affects one in four women, influenced by various age-specific risk factors.

Purpose of the Study:

  • To review risk factors and treatment options for recurrent urinary tract infections in women.
  • To explore current and emerging prophylactic and therapeutic strategies for UTIs.

Main Methods:

  • Literature review of risk factors, pathogens, and treatment modalities for recurrent UTIs.
  • Analysis of established and investigational preventive measures.

Main Results:

  • Key risk factors include sexual intercourse, contraception, antimicrobial use, estrogen, genetics, and urethral anatomy.

Related Experiment Videos

  • Escherichia coli is the most common pathogen implicated in UTIs.
  • Treatment options encompass long-term prophylaxis, post-intercourse therapy, patient-initiated treatment, estrogen, and cranberry juice.

    • Conclusions:

    • Recurrent UTIs in women are multifactorial, necessitating diverse treatment approaches.
    • Ongoing research focuses on novel preventive strategies, including vaccine development for severe cases.